Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia

About this update from Bausch Health Companies Inc.

LAVAL, QC, July 6, 2026 /PRNewswire/ -- Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), announces the listing of PrOKEDI® (extended-release injectable suspension of risperidone) 75 mg and 100 mg strengths to the drug formulary of the Régie de l'assurance maladie du Québec (RAMQ) effective June 25th, 2026, for the treatment of schizophrenia in adults. PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of schizophrenia in adults. According to the Canadian product monograph, PrOKEDI® achieves clinically relevant concentrations of the active ingredient within the first few hours after injection, without the need for a loading dose or oral supplementation. It provides sustained release over a 4-week dosing interval, without the need for oral supplementation or a loading dose.1 This decision marks an important milestone in securing reimbursement for PrOKEDI® in Quebec. This listing follows negotiations concluded earlier this year with the Pan-Canadian Pharmaceutical Alliance (APP). Bausch Health will continue its efforts with other provincial jurisdictions in accordance with their respective reimbursement processes. "This decision confirms the importance in providing timely access to innovative mental health treatments," said Amy Cairns, General Manager, Bausch Health, Canada Inc . "By making PrOKEDI® accessible, Québec is concretely improving the range of therapeutic options available to people living with schizophrenia." "The reimbursement of PrOKEDI® is excellent news. It provides psychiatrists and healthcare teams with an additional effective treatment option for patients, both in hospitals and in the community," said Dr Tin Ngo-Minh, MD, FRCPC . "The Québec Schizophrenia Society (SQS) welcomes the arrival of a new medication that is now accessible to people living with schizophrenia in Québec. Because each journey is unique and needs vary from one individual to another, it is essential that patients and their care teams have access to a range of treatment options. Each new medication represents another opportunity for individuals living with the condition to find a treatment that truly supports their recovery journey. For many individuals and families, increased access to therapeutic choices also brings hope and opens the door to new possibilities for well-being and stability," said Denis Tremblay, Director, Schizophrenia Society of Québec. About Schizophrenia Schizophrenia is a chronic and severe psychiatric disorder that typically emerges in late adolescence or early adulthood and affects about 1% of the population. The illness is characterized by episodes of psychosis and loss of contact with reality, as well as emotional and cognitive symptoms. It affects how a person thinks, feels, behaves, and relates to others, often impairing functioning, relationships, employment and quality of life.2  

View stock analysis, news, and events for Bausch Health Companies Inc.